In Vitro & In Vivo Diagnostic Substances Industry - SEC Form 4 Insider Trading Screener

Manufacturing Sector - Chemicals - In Vitro & In Vivo Diagnostic Substances
General
Tickers
Insider
Sh Price $
Lqdty M$
Date
Filing Date
  
Trade Date
  
Filing Delay
N Days Ago
Transaction Filing
P - Purchase
S - Sale
A - Grant
D - Sale to Iss
G - Gift
F - Tax
M - Option Ex
X - Option Ex
C - Cnv Deriv
W - Inherited
No deriv Multiple Days
Traded K$
Own Chg %
Industry
Insider Title   Officer
    COB
    CEO
    Pres
    COO
    CFO
    GC
    VP
  Director
  10% Own
  Other
Group by
Sort by
Max Results
Page
clear
Real-time CSV, Options, Alerts
100 results - Yahoo - Google - Finviz - Stockcharts - Tradingview - Stocktwits - SEC
TCcnt1d1w1m6m
P23+0+10+18+0
S68+0-0+1+34

X

Filing Date

Trade Date

Ticker

Company

Insider Name

Insider Title

Trade Type 

Share Price

Shares Traded

Shares Owned

Own chg

Value Traded

1d ret

1w ret

1m ret

6m ret

M
2017-05-19
NAVBNavidea Biopharmaceuticals, Inc.Latkin JedCOO, CFOP - Purchase$0.45+25,35942,559+147%+$11,426
2017-05-19
NEOGNeogen CorpBradley EdwardVPS - Sale$61.33-5,00096,512-5%-$306,659
2017-05-22
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$162.55-5,00045,256-10%-$812,769
2017-05-17
VRMLVermillion, Inc.Palmieri Valerie BarberPres, CEOP - Purchase$1.80+55559,097+1%+$999
2017-05-12
LNTHLantheus Holdings, Inc.Schaffer Derace LDirS - Sale$16.55-5,00058,730-8%-$82,750
2017-05-15
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale$14.66-10,000125,015-7%-$146,572
D
2017-05-12
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$61.29-48,469882,212-5%-$2,970,544
D
2017-05-11
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$62.01-8,107882,212-1%-$502,715
2017-05-10
LNTHLantheus Holdings, Inc.Schaffer Derace LDirS - Sale$15.75-10,00063,730-14%-$157,500
D
2017-05-10
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$162.69-27,0001,112,994-2%-$4,392,6270
D
2017-05-10
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale+OE$14.40-3,00017,174-15%-$43,2000
2017-05-09
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$13.40-3,000,0002,602,208-54%-$40,200,000+4
2017-05-09
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$13.40-3,000,0002,602,208-54%-$40,200,000+4
M
2017-05-08
OXFDOxford Immunotec Global PlcSchroeder Jeff R.Chief Commercial OfficerS - Sale$14.14-40,000127,147-24%-$565,6590
M
2017-05-08
OXFDOxford Immunotec Global PlcSchroeder Jeff R.Chief Commercial OfficerS - Sale$14.14-40,000127,147-24%-$565,6590
2017-05-09
LNTHLantheus Holdings, Inc.Schaffer Derace LDirS - Sale$14.75-10,00073,730-12%-$147,500-2
D
2017-05-05
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$160.61-26,0001,112,994-2%-$4,175,9380+1
D
2017-05-04
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$159.95-1,70019,852-8%-$271,91200
DM
2017-05-01
QDELQuidel Corp /de/Bujarski Robert JosephSVP, Bus Dev, GCS - Sale+OE$24.27-43,22537,759-53%-$1,048,9480+3
2017-05-02
ABIOArca Biopharma, Inc.Mitchell Daniel JDirP - Purchase$2.71+11,00011,000New+$29,810-3-6
DM
2017-04-26
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$24.16-36,000284,493-11%-$869,640+1+2
D
2017-04-27
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$63.68-2,67610,103-21%-$170,402-2-1
2017-04-06
NEOGNeogen CorpBradley EdwardVPS - Sale$61.54-21,018101,512-17%-$1,293,4220-2+3
D
2017-04-03
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.43-30,000461,668-6%-$463,0050+1-7
2017-04-03
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale$15.47-3,00017,174-15%-$46,4200+1-7
2017-04-03
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale$2.46-1,1141,275-47%-$2,740+40+5
2017-04-04
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale$2.41-41817,517-2%-$1,007+40+5
2017-04-04
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale$2.41-39014,045-3%-$940+40+5
2017-04-04
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale$2.41-72086,600-1%-$1,735+40+5
DM
2017-03-29
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.50-37,080284,493-12%-$834,204+10+8
2017-03-08
NYMXNymox Pharmaceutical CorpRobinson James GeorgeDirP - Purchase$3.59+50,0003,317,950+2%+$179,508+12+18+48
2017-03-24
ABIOArca Biopharma, Inc.Conway Robert EDirP - Purchase$2.59+25,00025,000New+$64,750-1-1-3
D
2017-03-20
OXFDOxford Immunotec Global PlcKeiley Elizabeth MSVP, GCS - Sale+OE$16.05-3,00030,614-9%-$48,150000
2017-03-17
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-17
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-17
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$12.20-3,000,0003,442,208-47%-$36,600,0000+30
2017-03-15
LNTHLantheus Holdings, Inc.Healey Timothy GSVP, CommercialS - Sale$12.42-11,31483,112-12%-$140,555-1-4-9
M
2017-03-13
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.43+2,00072,789+3%+$10,861+2+4-1
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Atlas Venture Associates Ix, L.P.10%S - Sale$13.91-21,1323,729,788-1%-$293,843+1+2-3
M
2017-03-09
NTLAIntellia Therapeutics, Inc.Formela Jean FrancoisDirS - Sale$13.91-21,1323,729,788-1%-$293,843+1+2-3
2017-02-28
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale$145.19-6,50014,950-30%-$943,7210+2+6
AD
2016-08-25
IDXXIdexx Laboratories Inc /deHenderson Rebecca MDirS - Sale+OE$110.44-9,92421,450-32%-$1,095,9530+2+6
D
2017-03-03
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale+OE$14.92-5,92348,271-11%-$88,38200+3
2017-03-01
IDXXIdexx Laboratories Inc /deKingsley Lawrence DDirP - Purchase$146.48+1,0001,135+741%+$146,480+1+1+6
D
2017-02-27
ABIOArca Biopharma, Inc.Selby Brian L.VP, FinanceS - Sale+OE$2.56-1612,389-6%-$4120-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Ozeroff Christopher DavidS.VP, GCS - Sale+OE$2.61-46517,935-3%-$1,2140-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Keuer Thomas ACOOS - Sale+OE$2.61-46514,435-3%-$1,2140-6+2
D
2017-02-28
ABIOArca Biopharma, Inc.Bristow Michael RPres, Chief Exec OfficS - Sale+OE$2.61-76387,320-1%-$1,9910-6+2
DM
2017-02-24
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$21.39-106,920280,306-28%-$2,287,314+5+5+5
D
2017-02-22
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$142.57-35,0001,108,947-3%-$4,990,1350+3+7
M
2017-02-22
MYGNMyriad Genetics IncHenderson John TDirP - Purchase$18.66+6,00042,824+16%+$111,930+1+3+2
2017-02-16
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$141.71-5,00050,256-9%-$708,5340+1+5
D
2017-02-17
VRMLVermillion, Inc.Feinberg Larry N* See Remarks, 10%P - Purchase$1.40+617,7319,825,289+7%+$864,823+18+21+23
D
2017-02-13
VRMLVermillion, Inc.Schuler Henri George10%P - Purchase$1.40+1,947,0528,109,840+32%+$2,725,873-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schuler Jack W10%P - Purchase$1.40+974,0819,805,249+11%+$1,363,713-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Jordan Veronica GhDirP - Purchase$1.40+6,69570,315+11%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Ferrara FredCOOP - Purchase$1.40+6,6956,695New+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Palmieri Valerie BarberPres, CEOP - Purchase$1.40+10,04258,542+21%+$14,059-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Schoen EricSVP Finance, CAOP - Purchase$1.40+3,34729,872+13%+$4,686-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Lafrance James TDirP - Purchase$1.40+6,695190,094+4%+$9,373-6+22+27
D
2017-02-13
VRMLVermillion, Inc.Burns James SDirP - Purchase$1.40+15,000265,922+6%+$21,000+11+33+38
D
2017-02-08
IDXXIdexx Laboratories Inc /deMcKeon Brian PEVP, CFOS - Sale+OE$141.63-9,92435,311-22%-$1,405,59100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$141.63-36,2501,088,486-3%-$5,134,17100+6
D
2017-02-08
IDXXIdexx Laboratories Inc /deJunius Daniel MDirS - Sale+OE$141.75-3,0002,495-55%-$425,26400+6
D
2017-02-06
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$13.36-25,000438,495-5%-$333,875+1+1+12
2017-02-02
VIVOMeridian Bioscience IncLueke MelissaEVP, CFOP - Purchase$12.59+4,000167,071+2%+$50,356+5+5+7
2017-01-26
VIVOMeridian Bioscience IncBaldini LawrenceEVP, Pres Global OperationsP - Purchase$12.70+4,000106,934+4%+$50,800+2+1+2
D
2017-01-09
NEOGNeogen CorpParnell Jack CDirS - Sale+OE$66.04-6,00013,555-31%-$396,222-10-1
D
2017-01-09
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$66.12-27,60039,583-41%-$1,824,796-10-1
D
2017-01-04
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$66.13-5,35210,103-35%-$353,9470+10
2017-01-04
BIOPBioptix, Inc.Honig Barry C10%P - Purchase$4.22+4,000443,585+1%+$16,880-5-19-32
D
2016-12-23
NEOGNeogen CorpMorrical Terri AVPS - Sale+OE$65.79-21,60039,583-35%-$1,421,006-1-2-4
D
2016-12-16
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.07-7,052443,314-2%-$106,241-1-1-10
D
2016-12-05
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-1,140443,3140%-$17,100+5+6+6
DM
2016-12-01
OXFDOxford Immunotec Global PlcWrighton-Smith PeterCEOS - Sale+OE$15.00-61,808443,314-12%-$927,120-100
2016-12-02
VIVOMeridian Bioscience IncElagin Vecheslav AEVP, Research, DevelopmentS - Sale$17.30-7,88353,003-13%-$136,376+2+3+2
DM
2016-11-30
QDELQuidel Corp /de/Bujarski Robert JosephSVP, Bus Dev, GCS - Sale+OE$22.84-60,00041,896-59%-$1,370,221+1+4-4
2016-12-01
APPYBioptix, Inc.Honig Barry C10%P - Purchase$5.04+29,815500,000+6%+$150,257+1-2
2016-11-30
VIVOMeridian Bioscience IncEllingwood Dwight EDirP - Purchase$17.12+1,0207,000+17%+$17,4660+3+2
DM
2016-11-28
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$119.78-27,4241,088,431-2%-$3,284,698-3-20
DM
2016-11-28
QDELQuidel Corp /de/Bryant Douglas CPres, CEOS - Sale+OE$22.89-72,000274,011-21%-$1,647,768-3-3-8
D
2016-11-25
QDELQuidel Corp /de/Tamerius JohnSVP, Strat, Ext AffairsS - Sale+OE$23.50-8,87823,540-27%-$208,633+1-3-8
D
2016-11-23
IDXXIdexx Laboratories Inc /deCraig ThomasDirS - Sale+OE$120.06-8,50024,283-26%-$1,020,519+1-40
2016-11-23
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale$62.95-1,0001,178,2890%-$62,950-1-2+6
D
2016-11-22
NEOGNeogen CorpBradley EdwardVPS - Sale+OE$61.16-21,600122,530-15%-$1,321,0520+1+4
2016-11-21
LNTHLantheus Holdings, Inc.Burgstahler David FDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Venkataraman SriramDir, 10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-21
LNTHLantheus Holdings, Inc.Avista Capital Partners Gp, LLC10%S - Sale$9.00-2,500,0004,282,208-37%-$22,500,000-1-8-13
2016-11-16
VIVOMeridian Bioscience IncEberly RichardEVP; Pres, Chief Comm OfficerS - Sale$17.00-4,92648,719-9%-$83,757-10+1
D
2016-11-14
NEOGNeogen CorpHerbert James LCOB, CEOS - Sale+OE$61.00-36,000886,212-4%-$2,195,982+1+3+7
2016-11-08
OXFDOxford Immunotec Global PlcEdwardson PeterChief Operations OfficerS - Sale$14.09-4,86948,932-9%-$68,615-10+3
D
2016-11-10
NEOGNeogen CorpYeutter Clayton KDirS - Sale+OE$59.00-4,500500-90%-$265,500-2+1+6
D
2016-11-14
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$61.28-3,00010,103-23%-$183,842-2+1+6
D
2016-11-09
NEOGNeogen CorpQuinlan Steven J.VP, CFOS - Sale+OE$57.93-3,00010,103-23%-$173,786-1-1+8
D
2016-11-09
IDXXIdexx Laboratories Inc /deAyers Jonathan WCOB, Pres, CEOS - Sale+OE$107.86-40,0001,085,855-4%-$4,314,1870+4+9+50
2016-11-08
IDXXIdexx Laboratories Inc /deEnd William TDirS - Sale$109.87-5,00048,654-9%-$549,3590+4+9+49
2016-11-08
OXFDOxford Immunotec Global PlcSandberg Richard ADirS - Sale$14.17-12,00020,174-37%-$170,007-1+1+3+2
M
2016-09-30
APPYVenaxis, Inc.Honig Barry C10%P - Purchase$2.52+63,42613,400-127%+$159,667-4+4+58
2016-11-07
ICCCImmucell Corp /de/Tomsche David ScottDirP - Purchase$5.19+4,00070,789+6%+$20,760+10+19+7
2016-11-04
VIVOMeridian Bioscience IncKraeutler John ACOB, CEOP - Purchase$16.13+5,000317,415+2%+$80,666+1+8+12-7

Real-time CSV? Options? Alerts? Contact us!
AAmended filing
DDerivative transaction in filing (usually option exercise)
EError detected in filing
MMultiple transactions in filing; earliest reported transaction date and weighted average transaction price
S - SaleSale of securities on an exchange or to another person
S - Sale+OESale of securities on an exchange or to another person (after option exercise)
F - TaxPayment of exercise price or tax liability using portion of securities received from the company
P - PurchasePurchase of securities on an exchange or from another person
Return to top